Humira

1. Humira
The companies: AbbVie, Eisai
Worldwide sales: $11.02 billion

AbbVie ($ABBV) rides Humira sales hard; the anti-inflammatory drug has churned out the majority of the company's revenue since Abbott Laboratories ($ABT) spun it off last January. In AbbVie's first full year on its own, its $10.7 billion from Humira made up 57% of overall sales, which tallied $18.8 billion.

Luckily for AbbVie, Humira's growth has shown no signs of slowing. Thanks to a score of additional indications as a treatment for ailments the likes of plaque psoriasis, Crohn's disease and ulcerative colitis, sales have nearly doubled since 2010's $5.5 billion haul. And in 2013 alone, Humira posted double-digit gains each quarter for AbbVie, with revenue increases from the year-ago period coming in at 16%, 13%, 19% and 13% in Q1, Q2, Q3 and Q4, respectively.

But no drug can stay at the top forever; Humira's patent protection is set to expire in 2016. And somewhat unsurprisingly, Humira's success has put a target on its back for biosimilar developers hungry for a piece of its revenues. A recent report from Moody's named AbbVie's drug as among the most sought-after prototypes for biosimilar copies; Novartis' ($NVS) Sandoz, for one, is well on its way with a version, starting Phase III trials in mid-December.

But until copycats hit, AbbVie plans to keep things going in the same direction. The company expects $19 billion in 2014 revenue, with Humira sales figuring in heavily.

For more:
Special Report:Top 10 rheumatoid arthritis drugs 2013
More Humira sales gains help AbbVie meet forecasts
Humira sales, up 19%, continue to carry AbbVie
Humira stays strong for AbbVie as drugmaker scrambles for new offerings

-- Carly Helfand (email | Twitter)

Humira
Read more on

Suggested Articles

Bluebird Bio has overcome a manufacturing hiccup that looked like it would delay its gene therapy launch in Europe until next year.

Lilly's top U.S. executive is on his way out. Enrique Conterno, who also heads up Lilly's global diabetes business, will step down at year's end.

GlaxoSmithKline, Pfizer, Sanofi and Boehringer Ingelheim are facing lawsuit claims that they failed to test for possible carcinogens in Zantac.